NCIt definition : A bispecific T-cell engager (BiTE) antibody directed against both the tumor-associated
antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17) and the T-cell surface
antigen CD3, with potential immunostimulating and antineoplastic activities. Upon
administration, alnuctamab binds bivalently to BCMA expressed on tumor cells and monovalently
to CD3 expressed on cytotoxic T-lymphocytes (CTLs). This activates and redirects CTLs
to BCMA-expressing tumor cells, which results in the CTL-mediated death of BCMA-expressing
tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that
is specifically overexpressed on malignant plasma cells, plays a key role in promoting
plasma cell survival.;
UNII : 7OSV6M6T4D;
CAS number : 2296827-07-9;
Molecule name : CC 93269; BMS-986349; BMS 986349; CC-93269; EM901;